Business
Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch
Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), ...
About this update from Hemostemix Inc
[{"type":"text","content":"Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health LaunchCalgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III autologous stem cell therapy company and Mr. Croom Lawrence are pleased to announce Croom has joined Hemostemix as its Chief Commercialization Officer, and partnered to offer MCI Screen through Hemostemix. MCI Screen is an FDA-approved and insurer-reimbursed advanced cognitive test for Vascular Dementia. Clinically, ACP-01 has been observed to reverse vascular dementia for more than ten years in one patient (Mrs L.).About Croom LawrenceCroom Lawrence is a seasoned biopharmaceutical executive with over 25 years of experience driving commercialization strategies across regenerative medicine, cell therapy, advanced biologics and diagnostics. He has successfully launched multiple breakthrough therapies, built and led high-performing global marketing and sales teams, and secured strategic partnerships with top-tier pharma and healthcare providers. His deep understanding of market access, reimbursement, and regulatory navigation positions him as a key asset to Hemostemix. By leveraging Croom's expertise, Hemostemix can accelerate the global adoption of ACP-01, expand its clinical and commercial footprint, and build sustainable revenue channels that align with our mission to restore health and save lives.\"I am very pleased to welcome Croom Lawrence as our Chief Commercialization Officer. Croom brings a rare blend of strategic insight and executional excellence, honed through decades of leadership in biotech commercialization. His track record in building global markets, negotiating complex partnerships, and accelerating the path from bench to bedside is unmatched. With Croom leading our commercialization efforts, Hemostemix is poised to unlock the full value of ACP-01 and transform patient care worldwide. The revenue share agreement with MCI Screen generates immediate significant revenue synergies,\" Smeenk said.Revenue Sharing Hemostemix and Acurist.AI (Croom Lawrence) have agreed to share revenue from each cognitive assessment such that 57% of revenue is allocated to Acurist.AI and 43% of revenue is allocated to Hemostemix from each patient examination, globally, assessed for an ACP-01 treatment.Acurist.AI adds to Hemostemix's Abilit...